Why two operations became the standard — and why that matters

For most of the past three decades, repairing a focal cartilage defect in the knee with a patient's own cells has meant two separate trips to theatre. The procedure — autologous chondrocyte implantation, first reported in 1994 — was built around a biological necessity: chondrocytes harvested from the knee are too few in number to fill a defect immediately, so they must be sent to an external laboratory and grown in culture for at least four weeks before they can be reimplanted.

In practice, that creates a particular kind of burden. The first operation is arthroscopic — a small biopsy of cartilage taken from a non-weight-bearing part of the knee, typically the margin of the femoral trochlea or the intercondylar notch, then shipped to a cell-culture facility preserved at 4°C. The second operation, weeks later, involves an open arthrotomy to place the expanded cells at the defect site under a protective membrane. Two anaesthetics, two hospital admissions, two recovery periods — and all of this while the original cartilage lesion remains unrepaired during the gap between them.

MACi (matrix-induced autologous chondrocyte implantation), which became the dominant modern variant, addressed some of the technical drawbacks of first-generation ACI by seeding the cultured cells onto a structured collagen membrane rather than using a periosteal patch. Clinically, it has proven durable: a minimum 10-year follow-up study of MACI in knee chondral defects reported sustained functional improvements, with an all-cause reoperation rate of 9% and progression to total knee replacement in 7.4% of patients over 10–17 years. That is a meaningful long-term benchmark. What MACI did not change was the underlying two-stage structure — and for a working-age patient, that structure carries real consequences: two periods off work, double the anaesthetic exposure, and months of uncertainty while the joint waits for its repair.

The question that follows naturally from this history is whether the cell-culture gap is truly unavoidable — or whether advances in intraoperative processing have made it possible to achieve equivalent cartilage restoration without the patient ever leaving theatre.

How STACI brings the laboratory into the operating theatre

The defining feature of STACI is logistical as much as biological: instead of a patient's cartilage cells travelling to an external facility for weeks of culture, a specialist laboratory team enters the operating theatre and performs cell processing alongside the surgical team — within the same anaesthetic.

The sequence works as follows. A small cartilage fragment is taken from a non-weight-bearing zone of the knee — an area that can be safely sampled without functional consequence. The fragment is treated with an enzyme that liberates the chondrocytes from the cartilage matrix without altering their biological character; it releases rather than manipulates them, removing the need for any external culture or expansion phase.

Simultaneously, bone marrow is drawn from within the surgical field, concentrated, and processed to isolate mesenchymal stem cells (MSCs). These are washed, examined under a microscope, and counted before use. MSCs act as signalling cells, releasing growth factors that guide and coordinate chondrocyte activity at the repair site — effectively a biological support crew that directs the restoration process from within the scaffold.

The combined chondrocyte-MSC population is then loaded onto a collagen-hyaluronan scaffold — a structured carrier that sits over the cartilage defect and holds the cells in position while new tissue forms. Platelet-rich plasma (PRP) may be added as a further growth stimulant.

The entire sequence — harvest, enzymatic liberation, MSC isolation, cell combination, scaffold loading, and implantation — is completed within one operative episode. STACI-specific clinical outcome data are still accumulating, and the technique is best understood as an emerging, advancing approach rather than one backed by the decades-long follow-up series that exist for two-stage MACI.

What the clinical evidence currently shows

Three distinct layers of evidence shape how confidently single-stage approaches can be assessed: established long-term data from two-stage MACI, emerging comparative trials covering the single-stage class broadly, and a STACI-specific dataset that is still in its early stages.

No head-to-head randomised trial comparing STACI directly against two-stage MACI or ACI has been published, and long-term STACI outcome data — five years or beyond — are not yet in the public literature. The MACI durability figures noted earlier (9% reoperation, 7.4% knee replacement conversion at 10–17 years) represent the benchmark that single-stage approaches must eventually demonstrate they can match; STACI has not yet produced equivalent follow-up series.

The closest available comparative evidence comes from two published studies. A 2025 matched-pair study (n=50) put single-stage minced cartilage implantation against two-stage ACI at 24 months: IKDC scores improved from 49.4 to 74.3 in the single-stage group and from 49.8 to 71.3 in the two-stage group — a difference that was not statistically significant. COMI and VAS pain scores, patient-acceptable symptom state achievement, and re-operation rates were all comparable. A separate six-year RCT comparing single-stage cultured MSC transplantation with two-stage ACI found no significant difference in patient-reported outcomes, MOCART cartilage repair scores, T2* mapping, or dGEMRIC values — confirming that cartilage quality parity is achievable without a two-stage structure. Neither trial used the specific intraoperative processing method that defines STACI; both function as supportive class-level evidence rather than direct proof.

On the economic side, published health economic modelling consistently favours single-stage approaches over two-stage procedures where clinical outcomes are equivalent, citing fewer hospital admissions and lower overall procedural cost.

Taken together, the available data are encouraging for the single-stage principle, but the evidence base for STACI specifically continues to accumulate. Treating short-to-medium follow-up results from adjacent techniques as confirmed long-term equivalence for STACI would go beyond what the current literature supports — this remains an evolving evidence base.

Which patients are suitable — and who is not

Patient selection for STACI rests on several intersecting factors — biological age, defect characteristics, and the overall condition of the joint — rather than any single threshold.

Age and biological health of the knee form the primary filter. STACI is typically considered for patients under 40 years of age, and possibly up to 45, where the joint retains the biological capacity to support cell-based regeneration. The relevant question is not chronological age alone but the biological state of the surrounding cartilage and subchondral bone, which clinical assessment and MRI can help characterise.

Defect type matters equally. STACI is suited to focal, full-thickness chondral lesions — the kind of discrete damage consistent with ICRS grade III–IV injury — in the size range typically addressed by ACI or MACI, broadly 2–10 cm². Extensive or pan-compartmental arthritis is a contraindication; where degeneration is widespread across the whole knee, cartilage repair of any kind is unlikely to be appropriate, and joint preservation or replacement planning becomes the more realistic conversation.

Multi-compartment involvement represents a practical area where STACI holds a logistical advantage. Damage affecting, for example, the medial femoral condyle and the patellofemoral joint can be addressed within a single operative session — an efficiency that managing the same pattern across two separate operations under two-stage ACI does not easily replicate.

Concomitant pathology — particularly malalignment — requires pre-operative consideration. Where load distribution across the repaired compartment is unfavourable, a corrective osteotomy may need to be planned alongside or in sequence with the cartilage procedure to protect the repair long term. Pre-operative planning supported by biomechanical assessment and detailed MRI cartilage imaging can help clarify these decisions before any commitment to surgery.

Recovery, rehabilitation, and practical differences

Planning recovery around either approach calls for the same fundamental mindset: ACI-class cartilage repair — single-stage or two-stage — is measured in months, not weeks. Patients who expect an early return to demanding physical activity will need to recalibrate before committing to either route.

For two-stage ACI and MACI, the published rehabilitation duration to higher-demand activity runs to approximately 12 months. Notably, that clock does not start at the first operation — the inter-stage laboratory period of four weeks or more means formal rehabilitation only begins after the second procedure. The total elapsed time from first biopsy to functional recovery is therefore longer than the 12-month figure alone implies.

Single-stage approaches are associated with fewer hospital admissions and the potential for a more streamlined recovery pathway, since there is no second admission and no enforced waiting gap between harvest and reimplantation. Health economic modelling supports this advantage where clinical outcomes are equivalent, citing one anaesthetic episode, one theatre booking, and reduced indirect costs — time off work, travel, and care arrangements — as meaningful gains. That said, a formally published rehabilitation protocol specific to STACI has not yet been reported; weight-bearing milestones and return-to-sport timelines remain those of the ACI class broadly, and patients should expect supervised physiotherapy extending well beyond the immediate post-operative period.

For those travelling from Lincolnshire or the wider non-London catchment, the practical difference between one and two theatre visits is worth discussing openly at consultation — particularly where caring responsibilities or occupational demands make scheduling a second procedure genuinely difficult.

Getting an assessment at Lincolnshire Knee

Deciding between STACI, two-stage MACI, or an alternative cartilage pathway depends on a structured clinical assessment — not a one-size-fits-all answer. Lincolnshire Knee is part of the MSK Doctors group and accepts patients without a GP referral and without NHS-style waiting lists.

Clinics are located at Sleaford NG34 — the group's head office, housing an Open MRI suite and Regeneration Hub — and at Grantham NG31 for consultation and diagnostics. Patients travelling from across the wider East Midlands or beyond are welcome at either site.

A first appointment would typically include clinical examination, review of any existing imaging, and where relevant an onMRI-based MRI cartilage analysis. That foundation allows a clear discussion of whether the defect size, the patient's biological age, and the overall joint condition make STACI, two-stage MACI, or another pathway the more appropriate fit.

For patients whose location makes a London base more practical, the group's London arm (LCC) offers the same consultant-led assessment.

To book without a referral, visit lincolnshireknee.co.uk.

1. [1] ACI, MACI, OAT and OCA improve knee function and pain — systematic review and meta-analysis. (2024). https://doi.org/10.1002/ksa.12525 https://doi.org/10.1002/ksa.12525
2. [2] Injectable cultured bone marrow derived mesenchymal cells vs chondrocytes in the treatment of chondral defects of the knee — RCT with 6 years follow-up. (2022). https://doi.org/10.1016/j.jcot.2022.101845 https://doi.org/10.1016/j.jcot.2022.101845
3. [3] Minced cartilage implantation provides comparable outcomes to autologous chondrocyte implantation (ACI) for knee cartilage lesions: A matched-pair analysis. (2025). https://doi.org/10.1002/ksa.70210 https://doi.org/10.1002/ksa.70210
4. [4] Minimum 10-Year Outcomes of Matrix-Induced Autologous Chondrocyte Implantation in the Knee. (2024). https://doi.org/10.1177/03635465231205309 https://doi.org/10.1177/03635465231205309
5. [5] Early health economic modelling of single-stage cartilage repair — guiding implementation of technologies in regenerative medicine. (2017). https://doi.org/10.1002/term.2197 https://doi.org/10.1002/term.2197
6. [6] Current solutions for the treatment of chronic articular cartilage defects in the knee. (2020). https://doi.org/10.1302/2058-5241.5.190031 https://doi.org/10.1302/2058-5241.5.190031
7. [7] Stem cell transplantation for the treatment of osteochondral defects of the knee: operative technique for a single-stage transplantation procedure using bone marrow-derived mesenchymal stem cells. (2020). https://doi.org/10.1016/j.knee.2020.05.004 https://doi.org/10.1016/j.knee.2020.05.004